HbA1c Test Misses Many Cases of Diabetes
|
By LabMedica International staff writers Posted on 02 Apr 2019 |
|
Image: The glycated hemoglobin or HbA1c test should not be solely used to determine the prevalence of diabetes (Photo courtesy of the Alberta Diabetes Foundation).
A glucose tolerance test, also known as the oral glucose tolerance test, measures the body's response to sugar (glucose). In this test, a person's blood is taken after an overnight fast, and then again two hours after they drink a sugary drink. The glucose tolerance test can be used to screen for type 2 diabetes.
The glycated hemoglobin (HbA1c) test shows the average level of blood sugar over the past two to three months. People who have diabetes usually have this test to see whether their blood sugar levels have been staying within a target range. This test is also used to diagnose type 1 and type 2 diabetes. It is often used to diagnose diabetes because no fasting or any preparation is required.
Endocrinologists at the City of Hope's Diabetes and Metabolism Research Institute (Duarte, CA, USA) included 9,000 adults without a diabetes diagnosis in a new study. The participants got both an HbA1c test and an oral tolerance glucose test, and the team compared the results. They found the HbA1c test did not catch 73% of diabetes cases that were detected by the oral glucose test. They found race and ethnicity had a significant impact on the accuracy of HbA1c. It was more likely to detect abnormal glucose levels in non-Hispanic whites than in non-Hispanic blacks or Hispanics.
Maria Mercedes Chang Villacreses, MD, the lead author of the study, said, “Based on our findings, HbA1c should not be solely used to determine the prevalence of diabetes. It should be used in conjunction with the oral glucose test for increased accuracy. The HbA1c test said some people had normal glucose levels when they didn't. Our results indicated that the prevalence of diabetes and normal glucose tolerance defined solely by HbA1c is highly unreliable, with a significant tendency for underestimation of the prevalence of diabetes and overestimation of normal glucose tolerance.” The study was presented on March 23, 2019, at the Endocrine Society's annual meeting held in New Orleans, LA, USA.
Related Links:
City of Hope's Diabetes and Metabolism Research Institute
The glycated hemoglobin (HbA1c) test shows the average level of blood sugar over the past two to three months. People who have diabetes usually have this test to see whether their blood sugar levels have been staying within a target range. This test is also used to diagnose type 1 and type 2 diabetes. It is often used to diagnose diabetes because no fasting or any preparation is required.
Endocrinologists at the City of Hope's Diabetes and Metabolism Research Institute (Duarte, CA, USA) included 9,000 adults without a diabetes diagnosis in a new study. The participants got both an HbA1c test and an oral tolerance glucose test, and the team compared the results. They found the HbA1c test did not catch 73% of diabetes cases that were detected by the oral glucose test. They found race and ethnicity had a significant impact on the accuracy of HbA1c. It was more likely to detect abnormal glucose levels in non-Hispanic whites than in non-Hispanic blacks or Hispanics.
Maria Mercedes Chang Villacreses, MD, the lead author of the study, said, “Based on our findings, HbA1c should not be solely used to determine the prevalence of diabetes. It should be used in conjunction with the oral glucose test for increased accuracy. The HbA1c test said some people had normal glucose levels when they didn't. Our results indicated that the prevalence of diabetes and normal glucose tolerance defined solely by HbA1c is highly unreliable, with a significant tendency for underestimation of the prevalence of diabetes and overestimation of normal glucose tolerance.” The study was presented on March 23, 2019, at the Endocrine Society's annual meeting held in New Orleans, LA, USA.
Related Links:
City of Hope's Diabetes and Metabolism Research Institute
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Chagas Disease Test
LIAISON Chagas
New
Pipet Controller
Stripettor Pro
Latest Clinical Chem. News
- AI-Powered Blood Test Accurately Detects Ovarian Cancer
- Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
- Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
- First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
- Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
Channels
Molecular Diagnostics
view channel
POC Oral Swab Test to Increase Chances of Pregnancy in IVF
Approximately 15% of couples of reproductive age experience involuntary childlessness. A significant reason for this is the growing trend of delaying family planning, a global shift that is expected to... Read more
Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections
Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more
Hematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
New Blood Test Detects Up to Five Infectious Diseases at POC
Researchers have developed a prototype flow-through assay capable of detecting up to five different infections, with results that can be quickly analyzed and transmitted via a specialized smartphone app.... Read more
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read more
Pathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read more
Technology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Qiagen Acquires NGS Analysis Software Company Genoox
QIAGEN (Venlo, the Netherlands) has signed a definitive agreement to acquire Genoox (Tel Aviv, Israel), a provider of artificial intelligence (AI)-powered software that enables clinical labs to scale and... Read more
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more